Cerus Corporation (CERS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 92 | 131 | 162 | 156 | 180 | 206 | 222 | 255 |
| Operating profit | $m | -9 | -2 | ||||||
| Net profit | $m | -60 | -54 | -43 | -37 | -21 | -16 | -7 | -8 |
| EPS reported | $ | -0.08 | -0.04 | ||||||
| Operating cashflow per share | $ | 0.06 | 0.01 | ||||||
| Capex per share | $ | 0.01 | 0.02 | ||||||
| FCF per share | $ | 0.04 | -0.01 | ||||||
| Free cash flow | $m | 9 | -2 | ||||||
| Net debt | $m | 1 | 9 | ||||||
| Book value equity | $m | 64 | 70 | ||||||
| Book value per share | $ | 0.34 | 0.35 | ||||||
| Number of shares | m | 190.59 | 200.57 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.11 | 5.61 | ||||||
| P/S LTM | x | 1.90 | 1.77 | ||||||
| P/FCF LTM | x | 46.07 | -214.67 | ||||||
| EV/EBITDA LTM | x | -85.17 | 161.49 | ||||||
| EV/Sales LTM | x | 2.28 | 2.62 | ||||||
| Earnings Yield LTM | % | -3.98% | -1.31% | ||||||
| FCF Yield | % | +2.17% | -0.47% | ||||||
| Quality | |||||||||
| ROE | % | -24.33% | -10.31% | ||||||
| ROIC | % | -5.19% | -1.06% | ||||||
| Operating margin | % | -4.21% | -0.73% | ||||||
| Gross margin | % | +54.47% | +52.05% | ||||||
| FCF/Sales | % | +4.13% | -0.83% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +14.35% | +22.90% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | 0.00% | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.09 | -0.02 | ||||||
| Net Debt/EBITDA | x | -13.96 | 20.23 | ||||||
| EBIT/Net interest | x | -1.04 | -0.21 | ||||||
| Net debt/market cap | % | +21.37% | +12.44% | ||||||
| Net debt/Equity | x | 0.02 | 0.12 | ||||||
| Gross debt/equity | x | 1.51 | 1.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free